BTG1 low expression in pancreatic ductal adenocarcinoma is associated with a poorer prognosis



BTG1 is a member of the TOB/BTG protein family, which is a transducer of ErbB-2 and TOB2. It is known to inhibit tumor genesis, but its role in pancreatic ductal adenocarcinoma (PDAC) is still unknown. The purpose of this study is to investigate the expression of BTG1 protein in PDAC and to determine its prognostic significance.


Immunohistochemistry is used to determine the protein expression of the BTG1 gene in 79 surgically resected PDAC. The association of BTG1 expression with all the patients’ clinicopathologic parameters, including survival, was analyzed using statistical software.


High BTG1 expression was observed in 27.8% (22/79) of the PDAC tissues, which was significantly lower than the 58.2% (46/79) of corresponding normal adjacent noncancerous tissues by immunohistochemical staining (p<0.001).Through the stratified analysis, we found a significant difference of BTG1 expression in peri-neural invasion (p = 0.002), T stage (p = 0.000), N stage (p = 0.018), and tumor, node, and metastasis stage (p = 0.000). Univariate and multivariate Cox analysis revealed that BTG1 expression status was an independent prognostic factor in PDAC (p = 0.027). Moreover, overall survival was better in PDAC cases with higher rather than lower BTG1 expression (p = 0.027).


This study demonstrated for the first time that lower expression of BTG1 might be involved in the progression of PDAC, suggesting that BTG1 might be a novel prognostic marker and a target for therapy.

Post author correction




Yufang Huang, Jiawei Zheng, Ting Tan, Li Song, Shanshan Huang, Yan Zhang, Lin Lin, Jingnan Liu, Peichan Zheng, Xiong Chen, Xi Chen, Xuenong Ouyang

Article History


Financial support: This work was funded by grants from the National Natural Science Foundation of China (No.81502360) and Natural Science Foundation of Fujian Province (No.2016J01576 and No.2016J01586 and No.2017J05121).
Conflict of interest: None of the authors has financial interest related to this study to disclose.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.



  • Department of Medical Oncology, Fuzhou General Hospital of Nanjing Military Command, Fuzong Clinical College of Fujian Medical University, Fujian - PR China
  • Burns and Plastic Surgery, Fuzhou General Hospital of Nanjing Military Command, Fuzhou, Fujian - PR China
  • Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang - PR China
  • Fujian Center for Safety Evaluation of New Drugs, Fujian Medical University, Fuzhou - PR China
  • School of Basic Medical Science, Putian University, Putian - PR China
  • Yufang Huang, Jiawei Zheng, and Ting Tan contributed equally to this study.

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.